Dans des modèles expérimentaux, une tolérance d'allogreffe a pu être induite en transférant des lymphocytes T CD4+ régulateurs (Treg) spécifiques d'antigènes (Ag) du donneur expandus ex vivo. Les données ont démontré l'importance des Treg d'allospécificité indirecte (Treg indirects) dans l'induction d'une tolérance à long terme. L'expansion de Treg indirects ex vivo est problématique, principalement à cause de la difficulté d'obtenir en grand nombre des cellules présentatrices d'antigène autologues (CPA)pour stimuler les Treg. Les lymphocytes B (LB) sont des APC accessibles, présentes en grand nombre et ont un fort potentiel régulateur. Cependant, l'utilisation de LB autologues comme APC est rendue problématique par leur incapacité à présenter les Ag dont ils ne sont pas spécifiques.Dans ce travail de thèse, nous avons développé une approche nanobiotechnologique permettant de transformer des LB polyclonaux autologues en puissants stimulateurs de Treg spécifiques de l'Ag.Des Ag particulaires synthétiques (SPAg) ont été générés en fixant sur des nanosphères fluorescentes de 400 nm de diamètre : (i) des anticorps monoclonaux dirigés contre un domaine constant de la chaine légère kappa du récepteur des LB, et (ii) des Ag modèles.Les SPAg se comportent comme des Ag particulaires naturels lorsqu'ils sont incubés in vitro avec des LB murins ou humains. Les SPAg se lient à la surface des LB kappa+, déclenchent un signal d'activation et sont internalisés dans leur endosomes. Les LB chargés en SPAg induisent l'activation et la prolifération des lymphocytes T CD4+ spécifiques de l'Ag in vitro.Des propriétés régulatrices peuvent être conférées aux LB chargés en SPAg en les stimulant avec du CpG. Les LB régulateurs générés n'induisent pas de prolifération des T CD4+ effecteurs mais, au contraire, entrainent une prolifération importante des Treg.Cette approche apparait comme une alternative innovante pour expandre des Treg spécifiques de l'Ag ex vivo / Allograft tolerance has been obtained in experimental models with adoptive transfer of ex vivo-expanded regulatory T cells (Treg) specific for donor antigens. Preclinical data have shown that Treg specific for indirectly presented alloantigens (indirect Treg) are mandatory for long-term tolerance. However, the ex vivo expansion of indirect Treg faces limitations,related essentially to the source of autologous antigen-presenting cells (APCs) used to stimulate T cells in vitro. B cells are (i) potent regulatory cells and (ii) APCs able to establish a privileged crosstalk with CD4+ T cells. However, the use of B cells as APCs is made problematic due to their inability to internalize and present non-cognate antigens. We have developed a novel nanobiotechnology-based approach to turn autologous polyclonal B cells into potent stimulators of antigen-specific T reg.Synthetic particulate antigens (SPAg) were generated by immobilizing (i) monoclonal antibodies directed against a framework region of B cell receptor (BCR) kappa-light chains and (ii) model antigens on fluorescent nanospheres of 400 nm in diameter.SPAg behaved like genuine particulate antigens when incubated in vitro with polyclonal murine B cells. SPAg bound to surface BCR of any kappa-positive B cells, triggered activation signal and were internalized in late endosomal compartment of B cells. SPAgloaded B cells induced activation and proliferation of antigen-specific T cells. This approach was transposable to humans’ cells. Importantly, regulatory properties could be conferred toSPAg-loaded B cells by CpG stimulation. SPAg-loaded regulatory B cells prevented proliferation of effector CD4+ T cells and induced proliferation of antigen-specific Treg in vitro.Autologous polyclonal B cells loaded with SPAg appear as an innovative platform to expand Treg ex vivo. This approach may improve the efficiency and costs of current procedures

L'activation de TLR9 par injection directe de nucléotides CpG non méthylés dans une tumeur peut induire une réponse immunitaire thérapeutique, mais les lymphocytes T régulateurs (Tregs) inhibent ensuite la réponse immunitaire antitumorale et limitent ainsi le pouvoir des stratégies d'immunothérapies contre le cancer.Chez des souris porteuses de tumeurs, nous avons constaté que les Tregs dans la tumeur expriment préférentiellement les marqueurs cellulaires de surface CTLA-4 et OX40. Nous montrons que la co-injection intratumorale d'anti-CTLA-4 et anti-OX40 avec du CpG en intra-tumoral aboutit à l’élimination des Tregs infiltrant la tumeur. Cette immunomodulation in situ, réalisée avec de faibles doses d'anticorps dans une tumeur unique, génère une réponse immunitaire antitumorale systémique capable d’éradiquer la maladie disséminée chez la souris. De plus, cette modalité de traitement est efficace contre des lésions de lymphome du SNC avec métastases leptoméningées, des sites qui sont généralement considérés comme des sanctuaires de cellules tumorales pour les traitements systémiques conventionnels.Ces résultats démontrent que les effecteurs immunitaires anti-tumoraux activés par immunomodulation locale peuventt éradiquer des cellules tumorales siègeant dans des sites éloignés. Nous proposons que, plutôt que d'utiliser des anticorps monoclonaux pour cibler les cellules cancéreuses par voie systémique, des anticorps monoclonaux pourraient être utilisés pour cibler les cellules immunitaires infiltrant la tumeur localement, provoquant ainsi une réponse immunitaire systémique. / Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, regulatory T-cells (Tregs) eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within the tumor preferentially express the cell surface markers CTLA-4 and OX40. We show that intratumoral coinjection of anti–CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. These results demonstrate that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. We propose that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response.

A endometriose (EDT) é caracterizada pela presença de tecido endometrial fora da cavidade uterina, e afeta mulheres em idade reprodutiva. Postulamos que alterações na frequência de células T reguladoras (Treg), natural killer (NK), supressoras mielóides (MDSC) e dendríticas (DC) no peritônio justificariam a redução da capacidade do sistema imune de reagir contra as células endometriais, permitindo sua implantação em locais ectópicos. Aqui, células Treg, NK, MDSC e DC foram quantificadas no fluido peritoneal (FP) e sangue de mulheres com EDT, a fim de associa-las ao desenvolvimento da doença; níveis de citocinas também foram avaliados. Na EDT, observou-se aumento na frequência de Treg, MDSC e DC no sangue e aparente redução destas no FP; ainda, a concentração de IL-12 foi menor no sangue comparadas ao grupo controle. Não foram observadas diferenças quanto às células NK e as outras citocinas analisadas. Os resultados indicam aumento da frequência de populações reguladoras em amostras de sangue de pacientes EDT, entretanto esses resultados não são refletidos no FP. / Endometriosis (EDT) is a gynecological disease characterized by the presence of endometrial cells out of the uterine cavity, which affects women in reproductive age. We postulated that alterations in the frequencies of regulatory T cells (Treg), natural killer cells (NK), myeloid-derived suppressor cells (MDSC) and dendritic cells (DC) in the peritoneum could justify the reduced capacity of the immune system to react to these ectopic endometrial cells, allowing them to invade distant tissues. Here, Treg, NK, MDSC and DC were quantified in the peritoneal fluid (PF) and peripheral blood (PB) of women with EDT, in order to associate them with the development of EDT; cytokine levels were also assessed. In EDT, higher frequencies of Treg, MDSC and DC in the PB and apparent lower frequencies of these cells in the PF were observed; IL-12 concentration was smaller in PB of EDT compared to control. No differences between groups were observed for NK cells and the other cytokines evaluated. The results indicate higher frequencies of regulatory cells in PB samples of EDT patients, although these findings were not reflected in PF samples.

Embora a fumaça do cigarro configure-se como o principal fator de risco para o desenvolvimento da DPOC, nem todos os fumantes desenvolvem a DPOC clinicamente significativa, sugerindo outros fatores intrínsecos ao indivíduo, como diferenças nas respostas imunológicas envolvidas na patogênese e progressão desta doença. Objetivos: Compreender melhor o papel da resposta imune adaptativa na progressão da DPOC. Métodos: Foram estudados amostras de tecidos pulmonares de 21 indivíduos não fumantes (grupo controle); 22 fumantes não obstrutivos (FNO) e 17 fumantes com DPOC. A densidade de células CD4+ e CD8+, células T regulatórias (Treg) FOXP3+, células B e células positivas para interleucinas IL-10 e IL-17, e citocinas como CCL19, BAFF e TGF-beta foram avaliadas em pequenas e grandes vias aéreas, e em tecidos linfoides associados ou não aos brônquios (BALT e iBALT, respectivamente). Resultados: Observamos um aumento das células T CD4+ e CD8+ em pequenas e grandes vias aéreas, BALT e iBALT em fumantes; no entanto, os valores mais elevados foram detectados em pequenas vias aéreas dos indíviduos DPOC. Além disso, observouse uma diminuição na expressão de TGF-? em pacientes com DPOC em comparação aos grupos de FNO e controle em pequenas e grandes vias aéreas ao passo que uma diminuição na densidade de Treg foi observado apenas em pequenas vias aéreas, com consequente diminuição da densidade de células positivas para IL-10 em pequenas e grandes vias aéreas. Em BALT observou-se uma resposta diferente, com um aumento na densidade de Treg no grupo DPOC, sem diferenças para as análises de IL-10. Houve um aumento da densidade de células positvas para IL-17 em pequenas e grandes vias aéreas e iBALT na DPOC. Conclusões: Observamos que a redução da atividade regulatória do processo inflamatório em pequenas vias aéreas e a progressão da obstrução em fumantes esteve associado à diminuição da densidade de células Treg e da expressão de IL-10 e aumento da expressão de IL-17. Além disso, verificou-se diferenças entre o perfil inflamatório nos compartimentos pulmonares estudados / Although cigarette smoke is configured as the primary risk factor for the development of COPD, not all smokers develop COPD clinically significant, suggesting that there are other factors intrinsic to the individual, such as differences in immune responses involved in the pathogenesis and progression of this disease. Objectives: To better understand the role of the adaptive immune response in the progression of COPD. Methods: Lung tissue samples from 21 nonsmokers were studied (control group); 22 non-obstructive smokers (NOS) and 17 COPD smokers. The density of CD4 + cells and CD8 + regulatory T cells (Treg) FOXP3 + cells, B cells and positive cells for interleukins IL-10 and IL-17, and cytokines as CCL19, BAFF and TGF-beta were evaluated in large and small airways, and lymphoid tissue associated with bronchi or not (BALT and iBALT, respectively). Results: We observed an increase in CD4 + T cells and CD8 + in small and large airways, BALT and iBALT in smokers; however, the highest amounts were detected in the small airways of COPD patients. Furthermore, there was a decrease in TGF-beta expression in COPD patients compared to FNO and control groups in large and small airways while a decrease in Treg density was observed only in small airway and consequent decrease in the density of cells positive for IL-10 in large and small airways. In BALT we observed a different response, with an increase in Treg density in COPD patients without differences in IL-10 analysis. There was an increase in cell density for IL-17 in large and small airways, and iBALT in COPD. Conclusions: We observed that reduction of inflammation regulatory activity in small airways obstruction and progression of smoking was associated with decreased Treg cell density and IL-10 expression and increased IL-17 expression. Furthermore, there are differences between the inflammatory profile in the lung compartments studied

Submitted by Renata Lopes (renatasil82@gmail.com) on 2016-05-17T14:40:56Z No. of bitstreams: 1 anaclaudiacarvalhogouveia.pdf: 2060044 bytes, checksum: a2757483182ff953fdffbf86f346380b (MD5) / Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2016-06-28T14:35:33Z (GMT) No. of bitstreams: 1 anaclaudiacarvalhogouveia.pdf: 2060044 bytes, checksum: a2757483182ff953fdffbf86f346380b (MD5) / Made available in DSpace on 2016-06-28T14:35:33Z (GMT). No. of bitstreams: 1 anaclaudiacarvalhogouveia.pdf: 2060044 bytes, checksum: a2757483182ff953fdffbf86f346380b (MD5) Previous issue date: 2012-08-30 / FAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais / A asma alérgica é uma doença inflamatória crônica das vias aéreas, caracterizada por uma resposta de hipersensibilidade imediata, obstrução brônquica, inflamação pulmonar e níveis elevados de IgE. A doença é mediada principalmente por uma resposta imunológica alérgeno-específica tipo Th2. Nas últimas décadas, a prevalência da asma alérgica tem aumentado significativamente, sobretudo nos países desenvolvidos. A Hipótese da Higiene atribui este aumento a uma menor exposição a determinados microrganismos durante a infância, quando o amadurecimento adequado do sistema imunológico requer estímulos que induzam respostas imunológicas de perfil Th1, fundamentais para o equilíbrio de respostas Th2 exacerbadas. Diversos trabalhos epidemiológicos parecem comprovar esta hipótese, evidenciando a existência de uma relação inversa entre o contato com microrganismos indutores de uma resposta Th1 e o desenvolvimento de asma alérgica. Paralelamente, estudos em modelos murinos constataram que o tratamento com Mycobacterium bovis BCG (BCG) reduz respostas Th2 alérgenoespecíficas. No entanto, os mecanismos pelos quais a micobactéria inibe o desenvolvimento da resposta alérgica são ainda pouco conhecidos. Este estudo avaliou o efeito da administração do BCG sobre a resposta imunológica ocorrida na alergia pulmonar em camundongos BALB/c previamente sensibilizados e desafiados com OVA. Vinte e quatro horas após o último desafio, o sangue e o lavado broncoalveolar foram coletados para análises de imunoglobulinas e contagem de células, respectivamente. Adicionalmente, os pulmões foram submetidos à análise histológica, avaliação da atividade de EPO e dosagens de citocinas e quimiocinas, assim como avaliação da expressão de CTLA-4, Foxp3 e IL-10 por citometria de fluxo. Os resultados obtidos indicam que o tratamento com BCG melhorou o processo alérgico através da redução dos principais parâmetros relacionados à resposta Th2, como o infiltrado eosinofílico pulmonar, a atividade de EPO, IL-4, IL-13, CCL11, além de IgE e IgG1 específicas anti-OVA. Por outro lado, a administração da micobactéria aumentou os níveis de IFN-γ, IL-10 e TGF-β, além das expressões de Foxp3 e CTLA-4 pelos linfócitos T CD4+. Paralelamente, houve um aumento na produção de IL-10 pelos linfócitos T CD8+. Esses dados sugerem que, além da indução de uma resposta imune Th1, a ação imunomoduladora do BCG está relacionada também à indução de mecanismos reguladores. / Atopic asthma is a chronic respiratory disease characterized by airway hyperresponsiveness, reversible airway obstruction, lung inflammation, and high levels of allergen-specific IgE, driven by allergen-specific Th2 cells. The increasing prevalence of allergic diseases, particularly in industrialized countries, has led to the hygiene hypothesis, which states that the newborn infant’s immune system is skewed toward Th2 responses and needs timely and appropriate environmental stimulus to create a balanced immune response. Supporting this hypothesis, epidemiological and experimental evidence has shown an inverse correlation between Th1-induced microbial infections and atopic asthma. Similarly, some animal studies have demonstrated that exposure to Mycobacterium tuberculosis or to environmental mycobacteria is able to protect against the development of allergic responses. However the exact mechanism underlying this inhibition still remains poorly understood. This study aimed to evaluate the ability of BCG to suppress an established allergic response in a mouse model of OVA-induced airway inflammation. To achieve this, OVA sensitized and challenged BALB/c mice were twice treated with BCG via nasal and 21 days after the first treatment, mice were rechallenged with OVA. Twenty-four hours after the last challenge, blood samples were collected to detect anti-OVA immunoglobulin isotypes, and bronchoalveolar lavage (BAL) was harvested for cell count. Additionally, lungs were collected for histological analysis, detection of EPO activity and measurement of cytokines and chemokines. The expression of CTLA-4, Foxp3 and IL-10 was also determined in lung tissue by flow cytometry. The data indicated that BCG treatment was able to inhibit an established allergic Th2-response by decreasing the allergen-induced eosinophilic inflammation, EPO activity, levels of IL-4, IL-13, CCL11 and serum levels of IgE and IgG1. Mycobacteria treatment increased lung levels of IFN-γ, IL-10 and TGF-β, and expressions of Foxp3 and CTLA-4 in CD4+T cells. Additionally, an increased production of IL-10 by CD8+ T cells was observed, even though no detectable changes in CD4+IL-10+ was noticed. Altogether, these results suggest that the mechanism underlying the down-regulatory effects of BCG on OVA-induced airway inflammation appear to be associated with the induction of both Th1 and T regulatory immune responses.

Les Cellules Dendritiques sont un groupe hétérogène de cellules présentatrices d’antigènes, importantes pour le contrôle des réponses innées et adaptatives. Les Cellules Dendritiques Plasmacytoïdes (pCD) en représentent une population unique, aux caractéristiques phénotypiques et fonctionnelles particulières, notamment par leur capacité à produire de grande quantité d’Interféron de type I (IFN). Cette signature IFN marque la physiopathologie du Lupus Erythémateux Systémique (LES), maladie auto-immune systémique. Les mécanismes à l’origine de cette production excessive d’IFN par les pCD restent incomplètement élucidés. Nous montrons, dans notre étude, chez l’homme comme dans un modèle murin que les plaquettes, activées dans le LES, participent à la production d’IFN via le CD40L. Cette production en excès d’IFN, a pour conséquence une maturation et activation d’autres Cellules Dendritiques (CD) entrainant l’activation inappropriée des lymphocytes T. Chez le sujet sain, cette activation inappropriée du système immunitaire adaptatif doit être strictement contrôlée afin d’assurer l’homéostasie du système immunitaire. Il a été montré précédemment que de nombreux lymphocytes aux caractéristiques phénotypiques de type mémoire-effecteur (TEM) peuplent les tissus périphériques, notamment le tissu cutané. Ces TEM sont capables de s’activer et proliférer localement en réponse à un stimulus. Les Cellules de Langerhans (LC) sont des cellules dendritiques résidant au niveau cutané dans l’épiderme. Leur fonction est à ce jour l’objet d’une controverse entre une fonction immuno-stimulante (modèle humain) et une fonction immuno-régulatrice (modèle murin). Nous démontrons dans cette étude que les LC, à l’état basal, chez l’homme, induisent la prolifération de Lymphocytes T régulateurs (Treg) au niveau cutané, capables de bloquer la stimulation inappropriée des TEM cutanés. Cependant en présence d’un stimulus infectieux, les LC induisent préférentiellement la prolifération des TEM en limitant celle des Treg. Les LC semblent être à la fois immuno-régulatrices ou stimulantes en fonction du contexte biologique auquel elles sont confrontées. / Dendritic Cell (DC) are a heterogeneous group of antigen-presenting leukocytes that are important in activation of both the innate and adaptative arms of the immune system. Plasmacytoid Dendritic Cells (pDC) represent a unique population, characterized by their ability to produce large amounts of type I Interferon (IFN). This « IFN signature » is a prominent feature of Systemic Lupus disease (SLE). Mechanisms leading to the excessive production of type I IFN remain largely unknown. Here, in our present study, we demonstrate that platelets are activated in SLE patients by circulating immune complexes and represent a major reservoir of CD40L. Activated platelets potentiate the production of type I IFN by pCD through a CD40L/CD40 interaction. Excessive production of type I IFN by pCD leads to DC activation and maturation and inappropriate activation of auto-reactive T cells.Under steady state condition, inappropriate activation of the immune system must be tightly controlled. It has been previously shown that normal adult human skin contains a large number of resident T cells (TRM) expressing the phenotype of Effector Memory T cells (TEM). These TEMTRM are specific for antigens previously encountered through skin and can be activated and proliferate under specific stimulation. Langerhans Cells (LC) are a group of skin resident DC living in epidermis. There is currently substantial controversy regarding the physiologic role of LC with regard to immunoregulation versus immunostimulation. Here we show that under steady state condition, LC induce the proliferation of a small subset of TRM. These proliferating TRM express the phenotype of TREG and are functional. However this stimulation of TREG could be reversed in the presence of foreign antigen in a dose-dependant fashion, as the addition of a pathogen to LC and TRM led to diminished TREG proliferation and increased TEM proliferation. These findings establish a novel immunological role for LC in human skin, allowing for the constitutive maintenance of tolerance, while also permitting the stimulation of resident immune memory in response to infectious challenge

La tolérance périphérique vis-à-vis de molécules potentiellement allergéniques en contact avec la peau joue un rôle essentiel pour prévenir le développement de l’eczéma allergique de contact (EAC). Au cours de ma thèse, j'ai contribué à l'identification des mécanismes et des acteurs responsables de l'induction de la tolérance par voie cutanée et à préciser le rôle respectif des sous-populations de cellules dendritiques (DC) cutanées dans la rupture de la tolérance et l'induction de lymphocytes T (LT) CD8+ initiant l'EAC. A l'aide d'un modèle murin d'induction de tolérance aux haptènes, j’ai pu montrer que les cellules de Langerhans (LC) épidermiques sont les cellules clés pour induire la tolérance cutanée et empêcher le développement d'un EAC médié par les LT CD8+. En effet, suite à l’application épicutanée d’un allergène/haptène faible, le DNTB, les LC migrent de la peau aux ganglions lymphatiques pour présenter l’antigène aux LT CD8+. Des expériences de déplétion in vivo et de transfert adoptif montrent que les LC sont responsables de la suppression de l’EAC en prévenant la différentiation des LT CD8+ spécifiques de l'allergène en cellules T cytotoxiques via deux mécanismes complémentaires: i) l’anergie/délétion des LT CD8+ et ii) l'activation de LT régulateurs Foxp3+ exprimant ICOS. Après avoir identifié des conditions d'immunisation conduisant au développement d'un EAC au DNTB, j'ai montré que la rupture de tolérance à ce type d'allergène est associée à i) à des modifications phénotypiques des LC épidermiques, ii) au recrutement rapide de monocytes inflammatoires Gr1+ dans la peau et iii) à une capacité équivalente des LC et des DC dermiques Langerin- à présenter l'allergène aux LT CD8+ dans les ganglions. Dans cette situation, les LC jouent un rôle pro-inflammatoire puisque leur déplétion réduit de manière dramatique l'induction de LT CD8+ effecteurs et l'EAC. Ces résultats indiquent que les LC jouent un rôle essentiel à la fois dans la prévention et dans l’induction de l’EAC, et que leur fonction tolérogène ou stimulatrice est vraisemblablement conditionnée par le microenvironnement cutané lors de la pénétration de l’allergène / Induction of peripheral tolerance to potentially allergenic molecules in contact with the skin is essential to prevent the development of allergic contact dermatitis (ACD). During my PhD, I contributed to the identification of the mechanisms and actors responsible for the induction of skin tolerance and clarified the respective roles of dendritic cell (DC) subsets in the breakdown of skin tolerance leading to the priming of cytotoxic CD8+ T cells and developpement of ACD. Using a mouse model of cutaneous tolerance to a model weak allergen, we show that epidermal Langerhans cells (LC) are essential to induce CD8+ T cell tolerance and prevent the development of ACD. Indeed, following the epicutaneous delivery of the weak allergen/hapten DNTB, LC were found to migrate from skin to draining lymph nodes to present the allergen to CD8+ T cells. Depletion and adoptive transfer experiments revealed that LC protect from development of ACD by preventing the priming of allergenspecific cytotoxic CD8+ T cells via two complementary mechanisms: i) anergy/deletion of allergen-specific CD8+ T cells and ii) activation of highly suppressive Foxp3+ regulatory T cells expressing ICOS. We identified DNTB skin delivery conditions that allow for CD8+ T cell priming and initiation of ACD. Breakdown of tolerance to this weak allergen was associated with i) phenotypic modifications of epidermal LC, ii) recruitment of inflammatory monocytes to the skin and iii) allergen presentation to CD8+ T cells by both LC and dermal Langerin- DC. In addition, LC are involved in tolerance breakdown as their depletion prior to skin immunization abrogated induction of CD8+ effector cells and ACD. These results demonstrate that LC are essential for both the induction of skin tolerance to weak skin allergens and for the induction of ACD, and suggest that their tolerogenic versus immuno-stimulatory function is likely dictated by signals from the skin microenvironment after penetration of the allergen

La Broncho-Pneumopathie Chronique Obstructive (BPCO) est caractérisée par une destruction du parenchyme pulmonaire, une obstruction des voies aériennes et une réponse inflammatoire anormale en réponse à un stress oxydant chronique lié au tabagisme. L’incidence accrue de la maladie chez les personnes âgées fait postuler que la sénescence cellulaire pourrait contribuer à la pathogenèse de la maladie. Une augmentation des marqueurs de stress oxydant et de sénescence est détectée dans le poumon des patients atteints de BCPO, associée à une diminution des lymphocytes T régulateurs (Treg : CD4+CD25highCD127-/low) et une augmentation d’une sous-population pro-inflammatoire Th17 (Th17 : CD45RO+CCR6+) parmi les lymphocytes T conventionnels (Tconv : CD4+CD127+) pulmonaires, alors que la fréquence des Treg est augmentée en périphérie. Différents marqueurs d’immunosénescence sont présents dans le sang périphérique des patients atteints de BPCO : raccourcissement des télomères des leucocytes, augmentation de la fréquence des lymphocytes T sénescents CD8+CD28- et CD4+CD28- ainsi que des CD4+CD57+. Cependant, le rôle causal d’une altération de la réponse au stress oxydant dans les anomalies et la sénescence des cellules immunes associées à la BPCO n’est pas établi / The Chronic obstructive pulmonary disease ( BPCO) is characterized by a destruction of the lung parenchyme, an obstruction of air traffics and an abnormal inflammatory answer in answer to an oxidizing stress chronicles smoking-related. The greater incidence of the disease at the elderly makes postulate(apply) that the cellular senescence could contribute to the pathogenesis of the disease

La thrombopénie immunologique ou purpura thrombopénique immunologique (PTI) est une maladie auto-immune rare responsable d’une destruction périphérique immunologique des plaquettes associée à une production médullaire inadaptée. Dans la première partie de ce travail, nous exposons les connaissances actuelles de sa physiopathologie ainsi que certaines données concernant la réponse immunitaire T, le rôle des lymphocytes T régulateurs (Treg), l’implication de la rate dans la réponse immunitaire ainsi que les modes d’action d’une thérapeutique anti-lymphocytaire B, le rituximab. Dans une seconde partie, nous rapportons les résultats obtenus chez 40 patients atteints de PTI. Nous avons montré que le taux des Treg circulants CD4+CD25HighFoxp3+ est similaire chez les patients et les témoins, avec une élévation de leur taux chez les sujets répondeurs aux traitements. A l’inverse, il existe un déficit quantitatif en Treg au sein de la rate des patients. L’analyse des sous-populations lymphocytaires B spléniques a montré une augmentation du taux de lymphocytes B de la zone marginale chez les patients. Concernant les mécanismes d’action du rituximab, nous avons montré qu’une déplétion lymphocytaire B sanguine et splénique n’est pas suffisante pour obtenir une rémission, et que les plasmocytes ne sont pas sensibles à cette thérapeutique. Par ailleurs, nous proposons un mécanisme d’échappement à ce traitement. En effet, nous avons montré que les patients résistants au RTX présentent une élévation du ratio Th1/Treg spléniques. Chez ces sujets non répondeurs, nous avons également observé une élévation du ratio lymphocytes T CD8+/CD4+, au sein de la rate, suggérant une participation des lymphocytes T cytotoxiques dans la physiopathologie du PTI. Ces résultats ouvrent donc de nouvelles perspectives dans la compréhension de la physiopathologie du PTI, notamment la possible implication des lymphocytes B de la zone marginale et le défaut de contrôle de la réponse immunitaire splénique par les Treg. Concernant le rituximab, son action sur la réponse immunitaire ne semble pas se limiter à une déplétion lymphocytaire B qui n’est pas suffisante pour obtenir une rémission. Un mécanisme d’échappement ou de résistance à cette thérapeutique passe par une orientation Th1 et une probable implication des lymphocytes T CD8+. / Immune thrombocytopenia (ITP) is an autoimmune disease responsible for a peripheral immune destruction of platelets associated with an inappropriate bone marrow production. In this work, we first review the mechanisms involved in the pathogenesis of ITP. We also focus on the T cell immune response, highlighting the key role of regulatory T cells (Treg) in peripheral tolerance. The implication of the spleen in the immune response and the effects of rituximab, a B cell depleting therapy, are discussed. Then, our results obtained from 40 ITP patients are reported. Despite the fact that CD4+CD25HighFoxp3+ circulating Treg levels are similar between patients and controls, a significant increase is observed in responder patients. In the spleen, the rate of Treg is lower in ITP patients. Analyses of the spleens also reveal an increase in the level of marginal zone B cells in ITP. Rituximab is responsible for a complete depletion of both circulating and splenic B cells, which is not sufficient to achieve a response. Moreover, plasma cells are still observed after treatment. An increase in the Th1/Treg ratio in the spleen of non responder patients after rituximab infusion could trigger an escape to this therapy. The involvement of CD8+ T cells in the pathogenesis of ITP is highlighted by the increase in the CD8+/CD4+ ratio in the spleen after rituximab. New fields in the understanding of the pathogenesis of ITP are opened with these results, particularly by showing a quantitative deficiency in splenic Treg and the possible involvement of marginal zone B cells. Regarding rituximab effect on the immune response, we demonstrate on the one hand that complete circulating and splenic B cell depletion is not sufficient to achieve remission, and on the other hand that Th1 response and increase in CD8+ T cells level may represent an escape to this treatment.

Les lymphocytes T régulateurs (Treg) jouent un rôle majeur dans la modulation de l’alloréactivité après allogreffe de cellules souches hématopoïétiques et permettent notamment de contrôler la réaction du greffon contre l’hôte (GVH) dans des modèles expérimentaux. Le potentiel thérapeutique des Treg est donc très important dans ce domaine, mais aussi dans l’auto-immunité ou en cancérologie. Cependant, de nombreuses barrières rendent difficile l’élaboration de stratégies thérapeutiques reposant sur le transfert adoptif de Treg chez l’homme et une meilleure compréhension des facteurs et mécanismes contrôlant la prolifération et les capacités suppressives de ces cellules permettrait de les cibler directement et si possible spécifiquement in vivo.Dans ce travail, après avoir élaboré un nouveau système d’évaluation clinique de la GVH chez la souris et démontré sa simplicité, sa reproductibilité et sa performance, nous avons pu montrer que l’action suppressive des Treg dans la GVH dépendait de l’interaction entre le TNFα produit par les lymphocytes T conventionnels (Tconv) du donneur et le récepteur TNFR2 exprimé par les Treg. En effet, en bloquant cette interaction de 3 façons différentes, à savoir par un anticorps monoclonal bloquant anti-TNFR2, ou en utilisant soit des Treg n’exprimant pas TNFR2 soit des Tconv ne produisant pas de TNFα, nous avons à chaque fois montré que l’effet protecteur des Treg était aboli en l’absence du signal TNF. Le récepteur TNFR2 étant exprimé préférentiellement par les Treg par rapport aux Tconv, nos résultats ouvrent la voie au ciblage des Treg in vivo via TNFR2, soit pour activer ce récepteur par un agoniste et donc stimuler les Treg afin de contrôler la GVH, soit à l’inverse pour bloquer l’axe TNFα/TNFR2 par un antagoniste et ainsi inhiber les Treg, ce qui permettrait alors de lever un frein à l’alloréactivité dans les situations où l’on cherche à la stimuler pour renforcer l’effet anti-tumoral, comme par exemple dans le cas des rechutes post-allogreffe. / Regulatory T cells (Tregs) are key players involved in the modulation of alloreactivity after hematopoietic stem cell transplantation. Indeed, Tregs can prevent graft-versus-host disease (GVHD) in experimental models. Therefore, the therapeutic potential of these cells in GVHD is substantial, as it is in other fields like auto-immunity or oncology. However, many obstacles still make the application of cellular therapy strategies based on the adoptive transfer of Tregs in humans quite complicated. A better understanding of factors and mechanisms that control the proliferation and suppressive capacities of Tregs could allow for a direct and specific targeting of these cells in vivo.In this work, after designing a new clinical grading system for murine GVHD and demonstrating its ease of use, reproducibility and performance, we have shown that the suppressive action of Tregs in GVHD depends on the interaction between TNFα produced by donor conventional T cells (Tconvs) and TNFR2 expressed by Tregs. Using 3 different ways to block this interaction, i.e. with an anti-TNFR2 blocking monoclonal antibody, or Tregs that do not express TNFR2 or donor Tconvs that cannot produce TNFα, we were able to show in each situation that blocking TNF signaling resulted in a loss of protection by Tregs. TNFR2 being highly expressed by Tregs as compared with Tconvs, our results pave the way for in vivo targeting of Tregs through TNFR2, either to activate this receptor with an agonist and therefore stimulate Tregs to control GVHD, or to block the TNFα/TNFR2 axis with an antagonist and in this case inhibit Tregs, which could boost alloreactivity, as expected in some particular settings like post-transplant relapse.